Aurobindo Pharma’s arm to acquire business assets from Profectus BioSciences

29 Nov 2019 Evaluate

Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., a clinical-stage vaccine development company. The assets are acquired for an upfront cash consideration $11.29 million with potential earn outs on achieving certain milestones.

The acquisition provides access to - Proprietary & Innovative technology platforms for Prophylactic use & Therapeutic use along with Global R&D center.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1162.80 -9.85 (-0.84%)
13-Jan-2026 12:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1715.65
Dr. Reddys Lab 1196.40
Cipla 1441.85
Zydus Lifesciences 893.20
Lupin 2169.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×